Just more than a month after it was announced, Dova Pharmaceuticals’ buyout by a Swedish biotech is complete.
The Durham drugmaker disclosed the news Sept. 30, that it was being acquired by Swedish Orphan Biovitrum (OM: SOBI).
According to a securities filing, SOBI paid about $868 million in cash.
Here's who's in line to profit from Dova's buyout
On Tuesday – the day the deal closed – Dova terminated and repaid a loan and security agreement among Dova, Silicon Valley Bank and others.